Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 1/20 | 0.55 |
| ▸ | EGFR | P00533 | 13/20 | 0.49 |
| ▸ | FBP1 | P09467 | 6/20 | 0.48 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.47 |
| ▸ | ERBB4 | Q15303 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2833454 | 0.87 | ENPP1 (0.57) | ENPP1EGFRFBP1ERBB2ERBB4 | |
| Hydrochloric Acid SCHEMBL2836487 | 0.83 | EGFR (0.50) | ENPP1EGFR | |
| SCHEMBL13969805 | 0.77 | ENPP1 (0.59) | ENPP1EGFRFBP1ERBB2ERBB4 | |
| SCHEMBL13091000 | 0.76 | ENPP1 (0.58) | ENPP1EGFRFBP1ERBB2ERBB4 | |
| SCHEMBL8812445 | 0.76 | ENPP1 (0.58) | ENPP1EGFRFBP1ERBB2ERBB4 | |
| SCHEMBL1013257 | 0.76 | ENPP1 (0.88) | ENPP1EGFRFBP1ERBB2ERBB4 | |
| SCHEMBL27866063 | 0.75 | ENPP1 (0.56) | ENPP1EGFRFBP1ERBB2ERBB4 | |
| SCHEMBL24393297 | 0.72 | ENPP1 (0.70) | ENPP1EGFRERBB2 | |
| SCHEMBL28608430 | 0.72 | ENPP1 (0.57) | ENPP1EGFRFBP1ERBB2ERBB4 | |
| SCHEMBL2834799 | 0.72 | ENPP1 (0.54) | ENPP1EGFRFBP1ERBB2ERBB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101878203-A | Novel 4-(tetrazol-5-yl)-quinazoline derivatives as anti cancer agents | NATCO PHARMA LTD | 2010-11-03 | — | — | CN | claimed |
| US-20100261740-A1 | NOVEL 4-(TETRAZOL-5-YL)-QUINAZOLINE DERIVATIVES AS ANTI CANCER AGENT | NATCO PHARMA LIMITED (IN) | 2010-10-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261740-A1 | NOVEL 4-(TETRAZOL-5-YL)-QUINAZOLINE DERIVATIVES AS ANTI CANCER AGENT | MKI67, CDKL5, CCNI | ENPP1 2397/4885EGFR 1110/4885FBP1 1224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.